Clinical Trial Update: Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and PK/PD of ACT500 in Metabolic dysfunction-associated steatohepatitis; recruitment has not yet begun.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis

Drugs mentioned

• ACT500

Snippet

Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Conditions: Metabolic Dysfunction-associated Steatohepatitis | Phase 1 | Status: NOT_YET_RECRUITING